Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
AVDL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.39 - $19.09
Previous CloseN/A
Volume358.54K
Average Volume (3M)1.29M
Market Cap
$828.11M
Enterprise Value$1.23B
Total Cash (Recent Filing)$35.79M
Total Debt (Recent Filing)$36.73M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 12, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding96,629,430
10 Day Avg. Volume897,964
30 Day Avg. Volume1,290,039
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.90
Price to Cash Flow (P/CF)26.30
P/FCF Ratio19.50
Enterprise Value/Market Cap1.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.02
Enterprise Value/Ebitda-34.68
Forecast
1Y Price Target
$17.13Price Target Upside108.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Avadel Pharmaceuticals News
PremiumCompany Announcements
Avadel Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
PremiumCompany Announcements
Geopolitical Shifts Threaten Avadel Pharmaceuticals’ Financial Stability
PremiumCompany Announcements
Avadel Pharmaceuticals Reports Strong Growth in 2024---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAvadel's 4Q24 top line met estimates, as expected, and management's initiatives should ultimately drive revenue growth.
Investor SentimentAvadel Pharmaceuticals' stock is considered to reflect far too pessimistic investor sentiment and wildly undervalues the opportunity of LUMRYZ in narcolepsy.
Sales EffortsManagement is seeing early positive indicators from the expanded sales force efforts to bring more patients into the funnel.
Bears Say
Investor SkepticismInvestors remain skeptical of the key metrics for the number of Lumryz patients and sales projections by the end of 2025.
Patient DiscontinuationDiscontinuation rates stood at 39% for switch patients and 62% for the new-to-oxybate and previously treated patient mix as of Q4 2024.
---
Ownership Overview
11.36% Insiders
11.35% Mutual Funds
37.49% Other Institutional Investors
31.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVDL FAQ
What was Avadel Pharmaceuticals’s price range in the past 12 months?
Avadel Pharmaceuticals lowest stock price was $7.39 and its highest was $19.09 in the past 12 months.
What is Avadel Pharmaceuticals’s market cap?
Avadel Pharmaceuticals’s market cap is $828.11M.
When is Avadel Pharmaceuticals’s upcoming earnings report date?
Avadel Pharmaceuticals’s upcoming earnings report date is May 12, 2025 which is in 47 days.
How were Avadel Pharmaceuticals’s earnings last quarter?
Avadel Pharmaceuticals released its earnings results on Mar 03, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.035 by -$0.015.
Is Avadel Pharmaceuticals overvalued?
According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Undervalued.
Does Avadel Pharmaceuticals pay dividends?
Avadel Pharmaceuticals does not currently pay dividends.
What is Avadel Pharmaceuticals’s EPS estimate?
Avadel Pharmaceuticals’s EPS estimate is -0.06.
How many shares outstanding does Avadel Pharmaceuticals have?
Avadel Pharmaceuticals has 96,629,430 shares outstanding.
What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?
Avadel Pharmaceuticals reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.035. Following the earnings report the stock price went down -4.551%.
Which hedge fund is a major shareholder of Avadel Pharmaceuticals?
Currently, no hedge funds are holding shares in AVDL
---
Avadel Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.13 (108.90% Upside)
$17.13 (108.90% Upside)
Blogger Sentiment
Bullish
AVDL Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 387.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $355.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.57%
12-Months-Change
Fundamentals
Return on Equity
-60.44%
Trailing 12-Months
Asset Growth
1.79%
Trailing 12-Months
Company Description
Avadel Pharmaceuticals
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
---
AVDL Company Deck
---
AVDL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects optimism around LUMRYZ's market performance and Avadel's strategic investments to drive growth. Despite legal uncertainties and challenges with patient switches and Q1 financial dynamics, the overall sentiment is positive, driven by strong uptake metrics and financial guidance.Read More>---
AVDL Stock 12 Month Forecast
Average Price Target
$17.13
▲(108.90% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Neurocrine
―
Supernus Pharmaceuticals
―
Heron Therapeutics
―
Xenon
―
Best Analysts Covering AVDL
1 Year
1 Year Success Rate
17/27 ratings generated profit
1 Year Average Return
+54.62%
reiterated a buy rating 22 days ago
Copying Ami Fadia's trades and holding each position for 1 Year would result in 62.96% of your transactions generating a profit, with an average return of +54.62% per trade.
---